

VACCINE

WORLD ASIA CONGRESS 2026

South East Asia

Southeast Asia Vaccine Partnerships & Investment Landscape 2026

Recent Collaborations, Licensing Deals &
Manufacturing Investments Across
Southeast Asia



STRATEGIC
PARTNERSHIPS



LICENSING
DEALS



MANUFACTURING
INVESTMENTS



STRONGER TOGETHER
HEALTHIER FUTURE

The region shaping the future of vaccines

Southeast Asia is rapidly emerging as one of the **fastest-growing regions** for vaccine innovation, manufacturing, and strategic partnerships.

Driven by growing healthcare demands, pandemic-preparedness initiatives, and supportive government policies, countries across the region are strengthening their capabilities through investments in research, local manufacturing, and international collaboration.

Technology transfer agreements, licensing partnerships, manufacturing expansions, and public–private initiatives are strengthening regional vaccine development, manufacturing capacity, and supply resilience. At the same time, global pharmaceutical companies are increasingly partnering with local manufacturers, research institutes, and governments to expand access to innovative vaccine technologies.

100M+

PLANNED ANNUAL DOSE
CAPACITY — VIETNAM
FACILITY

5

LANDMARK PARTNERSHIPS
PROFILED (2024–2026)

16

INDUSTRY LEADERS SPEAKING
AT VWSEA 2026

This report offers a snapshot of the partnerships, licensing agreements, manufacturing investments, and funding initiatives shaping Southeast Asia's vaccine landscape — and the leaders driving the conversation forward.

Deals defining the regional pipeline

Notable collaborations, licensing agreements, and manufacturing investments strengthening vaccine capacity and supply across Southeast Asia.

sanofi



Sanofi + VNVC



Vietnam

TECHNOLOGY TRANSFER & MANUFACTURING

Joint investment in a vaccine manufacturing facility with a planned annual production capacity of up to **100 million doses**, strengthening Vietnam's domestic vaccine production capabilities.

CEPI



CEPI + Hilleman Laboratories



Singapore

FUNDING & MANUFACTURING

Funding to support the manufacturing of investigational **Ebola vaccine** doses for clinical evaluation.

MERCK



Merck + Wellcome + Hilleman Laboratories



Singapore

MANUFACTURING COLLABORATION

Collaboration to manufacture investigational Ebola vaccine candidates for early-stage clinical development and future **outbreak response**.



Bio Farma + International Partners



Indonesia

TECHNOLOGY TRANSFER & STRATEGIC COLLABORATION

Continued international collaborations supporting vaccine production, technology transfer, product innovation, and regional **supply resilience**.



Takeda



Asia-Pacific

VACCINE COMMERCIALISATION

Continued expansion of **dengue vaccine** commercialization across Asia, supporting broader regional access to dengue prevention.

REGIONAL OUTLOOK

Southeast Asia is transitioning from a primarily procurement-driven market into a strategic hub for vaccine innovation, manufacturing, and international collaboration. Governments, multinational pharmaceutical companies, biotechnology firms, research institutions, and global health organizations are investing in partnerships that strengthen regional capabilities and improve long-term health security.

As technology transfer, manufacturing expansion, and collaborative research continue to grow, the region is well positioned to play an increasingly important role in the global vaccine ecosystem — while creating new opportunities for innovation, investment, and strategic partnerships.

Driving the conversation

Senior leaders from government agencies, international organizations, vaccine manufacturers, biotech companies, and research institutions convening to shape the future of vaccines across the region.

■ Government & Public Health



Dr. Mohd Azlan bin Zaharudin

Director, Malaysian Vaccine Project Office (MVPO), MOSTI



Malaysia



Dr. Vinod Kumar Bura

Coordinator, IVD Unit, WHO SEARO




India

■ International Organizations



Dr. Sushant Sahastrabudde

Deputy Director General, International Vaccine Institute (IVI)



South Korea



Indriana Permatasari

Project Manager, International Vaccine Institute (IVI)



Indonesia



Dr. Soleh Ayubi

Chief of Country Representative, PATH



Indonesia



Meenu Batolar

Global Regulatory Affairs Asia Pacific Lead, CEPI



Singapore



Dr. Mandeep Singh Dhingra

Director & Head, R&D Programs, CEPI



USA

■ Big Pharma & Biopharma



Badarulhisam Abdul Rahman, PhD

Chief Scientific Officer, Pharmaniaga Berhad



Malaysia



Zainab Sadat

General Manager, Vaccines, SEA & India MCO, Sanofi



Singapore



M. Indra Lamora

Director, Anti Infectious Department, Etana Technologies



Indonesia



Dr. Indra Rudiansyah

Project Lead, mRNA Vaccine Programme, Bio Farma



Indonesia



Neni Nurainy

Head of Translational Development of Life Science Product, Bio Farma



Indonesia



Dr. Wenshuo Zhou

Senior Director, R&D & CEO Scientific Assistant, Abogen Biosciences



China



Dr. Uma Nath Tripathi

Associate General Manager, Kashiv Biosciences LLC



India



Dr. Heba Wali

Vice CEO, VBC Vaccines and Biotechnology City



Egypt

■ Academia



Dr. Jetsumon Sattabongkot Prachumsri

Director, Mahidol Vivax Research Unit, Mahidol University



Thailand

— BE PART OF THE CONVERSATION

Join Vaccine World South East Asia 2026

Connect with leading stakeholders shaping Southeast Asia's vaccine ecosystem.
Discover new partnerships, gain actionable insights, and help shape the future of
vaccines in the region.

DATES

14–15 October 2026

Wednesday – Thursday

LOCATION

Jakarta, Indonesia

8th Vaccine World Asia Congress

FORMAT

In-Person Congress

Co-located with Biologics World SEA

Register Now →

imapac.com/events/vaccine-world-asia-congress-2026

VACCINE
WORLD ASIA CONGRESS 2026
South East Asia

Presented by IMAPAC
Vaccine World Asia Congress 2026 · South East Asia